Tested Applications
| Positive WB detected in | SH-SY5Y cells, HeLa cells, mouse testis tissue |
| Positive FC detected in | SH-SY5Y cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Flow Cytometry (FC) | FC : 0.40 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
22192-1-AP targets CHRNB4 in WB, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag16767 Product name: Recombinant human CHRNB4 protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 332-451 aa of BC096080 Sequence: WVKRCFLHKLPTFLFMKRPGPDSSPARAFPPSKSCVTKPEATATSTSPSNFYGNSMYFVNPASAASKSPAGSTPVAIPRDFWLRSSGRFRQDVQEALEGVSFIAQHMKNDDEDQSVVEDW Predict reactive species |
| Full Name | cholinergic receptor, nicotinic, beta 4 |
| Calculated Molecular Weight | 498 aa, 56 kDa |
| Observed Molecular Weight | 48-60 kDa |
| GenBank Accession Number | BC096080 |
| Gene Symbol | CHRNB4 |
| Gene ID (NCBI) | 1143 |
| RRID | AB_11232227 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P30926 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for CHRNB4 antibody 22192-1-AP | Download protocol |
| WB protocol for CHRNB4 antibody 22192-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The CHRNB4 Polyclonal antibody (Cat# 22192-1-AP) has 5 total citations published in Science Advances, Marine Drugs (×2), European Journal of Pharmacology, and Cancers (Basel). The associated research fields span Parkinson's disease and mitochondrial dysfunction, breast cancer, cervical cancer, lung cancer, and head and neck cancer, with most studies utilizing Western blot to examine nicotinic acetylcholine receptor subunit expression and therapeutic targeting.
| Species | Application | Title |
|---|---|---|
Mar Drugs Differential Expression of Nicotine Acetylcholine Receptors Associates with Human Breast Cancer and Mediates Antitumor Activity of αO-Conotoxin GeXIVA. | ||
Eur J Pharmacol Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of alpha-conotoxin TxID on lung cancer cell growth. | ||
Mar Drugs Cervical Cancer Correlates with the Differential Expression of Nicotinic Acetylcholine Receptors and Reveals Therapeutic Targets. | ||
Cancers (Basel) An Integrated Genomic Strategy to Identify CHRNB4 as a Diagnostic/Prognostic Biomarker for Targeted Therapy in Head and Neck Cancer.
|







